Reunert Ltd
F:REU1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Reunert Ltd
F:REU1
|
ZA |
|
CytoMed Therapeutics Ltd
F:F98
|
SG |
|
U
|
Udaipur Cement Works Ltd
BSE:530131
|
IN |
|
Surgical Science Sweden AB
F:4P41
|
SE |
|
C
|
Cheetah Mobile Inc
F:0C9A
|
CN |
Wall St Price Targets
REU1 Price Targets Summary
Reunert Ltd
According to Wall Street analysts, the average 1-year price target for REU1 is 6.64 EUR with a low forecast of 6.58 EUR and a high forecast of 6.84 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is REU1's stock price target?
Price Target
6.64
EUR
According to Wall Street analysts, the average 1-year price target for REU1 is 6.64 EUR with a low forecast of 6.58 EUR and a high forecast of 6.84 EUR.
What is the Revenue forecast for Reunert Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 8%.
What is the Gross Profit forecast for Reunert Ltd?
Projected CAGR
-18%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 4%. The projected CAGR for the next 3 years is -18%.
What is the Operating Income forecast for Reunert Ltd?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Operating Income has been 0%. The projected CAGR for the next 3 years is 11%.
What is the Pre-Tax Income forecast for Reunert Ltd?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 12%.
What is the Net Income forecast for Reunert Ltd?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 3 years is 16%.
